Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 6/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11418706 | 0.98 | MAOB (0.51) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL5571351 | 0.94 | MAOB (0.53) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL4319489 | 0.86 | MAOB (0.59) | MAOBMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5033268 | 0.86 | CYP19A1 (0.56) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL3321494 | 0.85 | MAOB (0.65) | MAOBMAPTL3MBTL1MRGPRX4 | |
| SCHEMBL5659691 | 0.84 | MAOB (0.58) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL14855144 | 0.83 | CCR5 (0.49) | MAOBMAOAMRGPRX4 | |
| SCHEMBL14855393 | 0.83 | MRGPRX4 (0.56) | MAOBMRGPRX4 | |
| SCHEMBL3204784 | 0.82 | CYP19A1 (0.44) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL26621350 | 0.82 | MAOB (0.47) | MAOBGAAMAPTMAOARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| CN-117466897-A | Highly selective FGFR2 inhibitors | 深圳福沃药业有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4034532-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | Exelixis, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114787144-A | Pyridone compounds and methods for modulating protein kinases | 埃克塞里艾克西斯公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022082876-A1 | TARGETED PROTEIN DEGRADATION-BASED C-MET DEGRADING AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州大学 | 2022-04-28 | — | — | WO | disclosed |
| CN-112239469-B | Targeted protein degradation c-Met degradation agent and preparation method and application thereof | 苏州大学 | 2021-09-28 | — | — | CN | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| WO-1999035146-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| US-5843966-A | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0720609-B1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| US-5703240-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| US-5622967-A | NERVOUS SYSTEM DISORDERS | STERLING WINTHROP, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| CN-1135218-A | Piperidine derivatives | GLAXO GROUP LTD (GB) | 1996-11-06 | — | — | CN | disclosed |
| EP-0720609-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| WO-1995008549-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | MAOB 793/4885GAA 2746/4885MAPT 2493/4885 |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | MAOB 793/4885GAA 2746/4885MAPT 2493/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | MAOB 1371/4885GAA 3255/4885MAPT 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.